Home

Catherine Coste

CIK 1821432 · last filed 2026-02-26

Catherine Coste is a corporate insider who has filed 12 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing, for BLFS, was dated Feb 26, 2026. Across all open-market trades the lifetime net is +$56.1K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $461.0K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$461.0K

Companies

4

Total Filings

12

Lifetime Open-Market Net

$56.1K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BLFS Director 13,871 $31.26 $433.6K $0 2 2026-02-26
BMRA Director 17,237 $1.59 $27.4K $56.1K 7 2024-12-17
Renalytix plc (RNLX) Delisted Director — $0.21 — $0 2 2023-11-22
MINERVA SURGICAL INC (UTRS) Delisted Director 6,479 $0.00 $1 $0 1 2022-06-14

Recent Filings

12 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-02-26 BLFS Grant (A) +8,170 $0 EDGAR
2025-03-20 BLFS Grant (A) +5,701 $0 EDGAR
2024-12-17 BMRA Grant (A) +85,000 $26.4K EDGAR
2023-12-14 BMRA Grant (A) — $0 EDGAR
2023-12-11 BMRA Grant (A) — $0 EDGAR
2023-11-22 Renalytix plc (RNLX) Delisted Grant (A) — $0 EDGAR
2023-07-07 Renalytix plc (RNLX) Delisted Grant (A) — $0 EDGAR
2023-01-30 BMRA Buy (P) +2,190 $6.5K EDGAR
2022-06-14 MINERVA SURGICAL INC (UTRS) Delisted Grant (A) +49,792 $120.0K EDGAR
2021-12-10 BMRA Grant (A) — $0 EDGAR
Showing 1–10 of 12
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.